Switch theme
Sign up to access all valuation multiples
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
2019
62
LTM Revenue $3K
LTM EBITDA -$117M
$582M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Enliven Therapeutics has a last 12-month revenue (LTM) of $3K and a last 12-month EBITDA of -$117M.
In the most recent fiscal year, Enliven Therapeutics achieved revenue of n/a and an EBITDA of -$104M.
Enliven Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Enliven Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3K | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $3K | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$117M | XXX | -$104M | XXX | XXX | XXX |
| EBITDA Margin | -3974164% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$117M | XXX | -$105M | XXX | XXX | XXX |
| EBIT Margin | -3952490% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$101M | XXX | -$89.0M | XXX | XXX | XXX |
| Net Margin | -3413765% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Enliven Therapeutics's stock price is $18.
Enliven Therapeutics has current market cap of $871M, and EV of $582M.
See Enliven Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $582M | $871M | XXX | XXX | XXX | XXX | $-2.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Enliven Therapeutics has market cap of $871M and EV of $582M.
Enliven Therapeutics's trades at n/a EV/Revenue multiple, and -5.6x EV/EBITDA.
Equity research analysts estimate Enliven Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Enliven Therapeutics has a P/E ratio of -8.6x.
See valuation multiples for Enliven Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $871M | XXX | $871M | XXX | XXX | XXX |
| EV (current) | $582M | XXX | $582M | XXX | XXX | XXX |
| EV/Revenue | 196966.7x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -5.0x | XXX | -5.6x | XXX | XXX | XXX |
| EV/EBIT | -5.0x | XXX | -5.6x | XXX | XXX | XXX |
| EV/Gross Profit | 196966.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -8.6x | XXX | -9.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -7.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEnliven Therapeutics's last 12 month revenue growth is 142%
Enliven Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.7M for the same period.
Enliven Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Enliven Therapeutics's rule of X is -3973810% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Enliven Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 142% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -3974164% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 37% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -3973810% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Enliven Therapeutics acquired XXX companies to date.
Last acquisition by Enliven Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Enliven Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Enliven Therapeutics founded? | Enliven Therapeutics was founded in 2019. |
| Where is Enliven Therapeutics headquartered? | Enliven Therapeutics is headquartered in United States of America. |
| How many employees does Enliven Therapeutics have? | As of today, Enliven Therapeutics has 62 employees. |
| Who is the CEO of Enliven Therapeutics? | Enliven Therapeutics's CEO is Mr. Sam Kintz, M.B.A.. |
| Is Enliven Therapeutics publicy listed? | Yes, Enliven Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Enliven Therapeutics? | Enliven Therapeutics trades under ELVN ticker. |
| When did Enliven Therapeutics go public? | Enliven Therapeutics went public in 2023. |
| Who are competitors of Enliven Therapeutics? | Similar companies to Enliven Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Enliven Therapeutics? | Enliven Therapeutics's current market cap is $871M |
| What is the current revenue of Enliven Therapeutics? | Enliven Therapeutics's last 12 months revenue is $3K. |
| What is the current revenue growth of Enliven Therapeutics? | Enliven Therapeutics revenue growth (NTM/LTM) is 142%. |
| What is the current EV/Revenue multiple of Enliven Therapeutics? | Current revenue multiple of Enliven Therapeutics is 196966.7x. |
| Is Enliven Therapeutics profitable? | Yes, Enliven Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Enliven Therapeutics? | Enliven Therapeutics's last 12 months EBITDA is -$117M. |
| What is Enliven Therapeutics's EBITDA margin? | Enliven Therapeutics's last 12 months EBITDA margin is -3974164%. |
| What is the current EV/EBITDA multiple of Enliven Therapeutics? | Current EBITDA multiple of Enliven Therapeutics is -5.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
